New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding
This article was originally published in The Pink Sheet Daily
The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.
You may also be interested in...
Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.
Forma Therapeutics has already convinced several big industry partners its discovery engine will yield oncology candidates in emerging areas of research. Now it wants to find academic groups to help feed its engine, all while the resurgent biotech IPO market might make its unusual structure superfluous.
New and existing investors back early clinical studies by leading U.K. stem cell company ReNeuron, including potential therapies for stroke, limb ischemia, and retinitis pigmentosa, as well as other sight destroying conditions like age-related macular degeneration.